• Explore /
  • Poster
  • / A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).

A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).

Abstract Video & Slides Poster

Authors

null

Amy Elizabeth Dezern

Johns Hopkins University, Baltimore, MD

Amy Elizabeth Dezern , Giovanni Marconi , Dries Deeren , Maria Diez Campelo , Michael Lübbert , Pramila Krishnamurthy , Zsolt Nagy , Grzegorz Basak , Elena Morozova , Klaus Geissler , Yishai Ofran , Heather Kelley , Angela Volkert , Kristen Baker , Qing Kang-Fortner , Catherine Madigan , David A. Roth , Michael Kelly , Pierre Fenaux

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT04797780

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7075)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7075

Abstract #

TPS7075

Poster Bd #

300a

Abstract Disclosures

Similar Posters

First Author: Rachel J. Cook

First Author: Eric Huselton

First Author: Chun Yew Fong

First Author: Eunice S. Wang